Thu, November 16, 2017
Wed, November 15, 2017
Tue, November 14, 2017

Derek Archila Maintained (URGN) at Buy with Increased Target to $51 on, Nov 15th, 2017

Derek Archila of Oppenheimer, Maintained "UroGen Pharma Ltd." (URGN) at Buy with Increased Target from $32 to $51 on, Nov 15th, 2017.

Derek has made no other calls on URGN in the last 4 months.



There is 1 other peer that has a rating on URGN. Out of the 1 peers that are also analyzing URGN, 0 agree with Derek's Rating of Hold.



This is the rating of the analyst that currently disagrees with Derek


  • Michael Yee of "Jefferies" Maintained at Strong Buy with Increased Target to $37 on, Monday, October 9th, 2017